# ![@OzmosiHealth Avatar](https://lunarcrush.com/gi/w:26/cr:twitter::1055982930.png) @OzmosiHealth Ozmosi

Ozmosi posts on X about more info, health, $xbi, $ibb the most. They currently have [-----] followers and [---] posts still getting attention that total [-----] engagements in the last [--] hours.

### Engagements: [-----] [#](/creator/twitter::1055982930/interactions)
![Engagements Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::1055982930/c:line/m:interactions.svg)

- [--] Week [------] +12%
- [--] Month [------] -20%
- [--] Months [-------] +24%
- [--] Year [---------] +23%

### Mentions: [---] [#](/creator/twitter::1055982930/posts_active)
![Mentions Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::1055982930/c:line/m:posts_active.svg)

- [--] Week [---] -6.60%
- [--] Month [---] +14%
- [--] Months [-----] +8.50%
- [--] Year [-----] -0.71%

### Followers: [-----] [#](/creator/twitter::1055982930/followers)
![Followers Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::1055982930/c:line/m:followers.svg)

- [--] Week [-----] +0.33%
- [--] Month [-----] +0.53%
- [--] Months [-----] +14%
- [--] Year [-----] +43%

### CreatorRank: [-------] [#](/creator/twitter::1055982930/influencer_rank)
![CreatorRank Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::1055982930/c:line/m:influencer_rank.svg)

### Social Influence

**Social category influence**
[stocks](/list/stocks)  55.41% [countries](/list/countries)  4.92% [cryptocurrencies](/list/cryptocurrencies)  4.92% [finance](/list/finance)  0.33% [technology brands](/list/technology-brands)  0.33%

**Social topic influence**
[more info](/topic/more-info) #304, [health](/topic/health) 3.28%, [$xbi](/topic/$xbi) 2.95%, [$ibb](/topic/$ibb) 2.95%, [$xph](/topic/$xph) 2.95%, [$pph](/topic/$pph) 2.95%, [canada](/topic/canada) 2.95%, [data](/topic/data) 2.62%, [the first](/topic/the-first) 2.62%, [bio](/topic/bio) 2.3%

**Top accounts mentioned or mentioned by**
[@wallstreet_dawg](/creator/undefined)

**Top assets mentioned**
[Cognition Therapeutics, Inc. (CGTX)](/topic/$cgtx) [Merck & Co., Inc. (MRK)](/topic/$mrk) [Tenaya Therapeutics, Inc.  (TNYA)](/topic/$tnya) [Denali Therapeutics Inc. Common Stock (DNLI)](/topic/$dnli) [Cullinan Management, Inc. (CGEM)](/topic/$cgem) [Coya Therapeutics, Inc. (COYA)](/topic/$coya) [SuperRare (RARE)](/topic/$rare) [Mirum Pharmaceuticals, Inc. Common Stock (MIRM)](/topic/$mirm) [Roivant Sciences Ltd. Common Shares (ROIV)](/topic/$roiv) [Synthetify (SNY)](/topic/$sny) [Upstream Bio, Inc. (UPB)](/topic/$upb) [Elevai Labs, Inc. (ELAB)](/topic/$elab) [Xilio Therapeutics, Inc. (XLO)](/topic/$xlo) [Atai Life Sciences B.V. (ATAI)](/topic/atai-life) [Invivyd, Inc. (IVVD)](/topic/$ivvd) [TG Therapeutics, Inc. (TGTX)](/topic/$tgtx) [Biogen Inc (BIIB)](/topic/$biib) [MapLight Therapeutics, Inc (MPLT)](/topic/$mplt) [Zenas BioPharma, Inc. (ZBIO)](/topic/$zbio) [CRISPR Therapeutics AG (CRSP)](/topic/$crsp) [Sagimet Biosciences Inc. (SGMT)](/topic/$sgmt) [Kymera Therapeutics, Inc. (KYMR)](/topic/$kymr) [Sanofi (SNY)](/topic/sanofi) [Immunocore Holdings Limited (IMCR)](/topic/$imcr) [Nurix Therapeutics, Inc. (NRIX)](/topic/$nrix) [Harmony Biosciences Holdings, Inc. (HRMY)](/topic/$hrmy) [Biomea Fusion, Inc. (BMEA)](/topic/$bmea) [Werewolf Therapeutics, Inc. (HOWL)](/topic/$howl) [Incyte Corporation (INCY)](/topic/$incy) [Exelixis Inc (EXEL)](/topic/$exel) [Viridian Therapeutics, Inc. Common Stock (VRDN)](/topic/$vrdn) [ALX Oncology Holdings Inc (ALXO)](/topic/$alxo) [Pasithea Therapeutics Corp. (KTTA)](/topic/$ktta) [IN8bio, Inc. (INAB)](/topic/$inab) [Oruka Therapeutics, Inc. Common Stock (ORKA)](/topic/$orka) [C4 Therapeutics, Inc (CCCC)](/topic/$cccc) [Nasus Pharma Ltd (NSRX)](/topic/$nsrx) [Actuate Therapeutics, Inc. (ACTU)](/topic/$actu) [Relay Therapeutics, Inc. (RLAY)](/topic/$rlay) [4D Molecular Therapeutics Inc. (FDMT)](/topic/$fdmt) [Evommune, Inc. (EVMN)](/topic/$evmn) [Viking Therapeutics, Inc (VKTX)](/topic/$vktx) [NeuroSense Therapeutics Ltd. (NRSN)](/topic/$nrsn) [Alnylam Pharmaceuticals, Inc. (ALNY)](/topic/$alny) [Annovis Bio Inc. (ANVS)](/topic/$anvs) [Vertex Protocol (VRTX)](/topic/$vrtx) [AB (prev. Newton) (AB)](/topic/$ab) [BridgeBio Pharma, Inc. Common Stock (BBIO)](/topic/$bbio) [Adlai Nortye Ltd (ANL)](/topic/$anl) [Taysha Gene Therapies, Inc. (TSHA)](/topic/$tsha) [Alto Neuroscience, Inc. (ANRO)](/topic/$anro) [OS Therapies Incorporated (OSTX)](/topic/$ostx) [Taraxa (TARA)](/topic/$tara) [Arcellx, Inc. (ACLX)](/topic/$aclx) [Caribou Biosciences, Inc. (CRBU)](/topic/$crbu) [Septerna, Inc. (SEPN)](/topic/$sepn)
### Top Social Posts
Top posts by engagements in the last [--] hours

"$UPB Upstream Bio announced they will present P2 Asthma results on 2026-02-11 for Verekitug More Info: https://pryzm.ozmosi.com/product/26311 https://pryzm.ozmosi.com/product/26311"  
[X Link](https://x.com/OzmosiHealth/status/2021650489511948616)  2026-02-11T18:20Z [----] followers, [---] engagements


"$ELAB Elevai Labs obtains exclusive license for two muscle loss prevention assets plans to develop in combination with GLP-1 obesity treatments. More Info: $XBI $IBB $XPH $PPH https://pryzm.ozmosi.com/product/11908 https://pryzm.ozmosi.com/product/11908"  
[X Link](https://x.com/OzmosiHealth/status/1785656049477009480)  2024-05-01T13:02Z [----] followers, [---] engagements


"$ELAB Elevai Labs obtains exclusive license for two muscle loss prevention assets to develop along with GLP-1 obesity treatments. More Info: $XBI $IBB $XPH $PPH https://pryzm.ozmosi.com/product/11908 https://pryzm.ozmosi.com/product/11908"  
[X Link](https://x.com/OzmosiHealth/status/1785667379038699669)  2024-05-01T13:47Z [----] followers, [---] engagements


"$ELAB Elevai Labs secures rights to two muscle loss prevention assets to be combined with GLP-1 obesity treatments. More Info: $XBI $IBB $XPH $PPH https://pryzm.ozmosi.com/product/11908 https://pryzm.ozmosi.com/product/11908"  
[X Link](https://x.com/OzmosiHealth/status/1785671150137376992)  2024-05-01T14:02Z [----] followers, [---] engagements


"$OCGN Ocugen reveals promising early results for OCU410 a new gene therapy for treating dry age-related macular degeneration. More Info: $XBI $IBB $XPH $PPH https://pryzm.ozmosi.com/product/27030 https://pryzm.ozmosi.com/product/27030"  
[X Link](https://x.com/OzmosiHealth/status/1858850741609525367)  2024-11-19T12:32Z [----] followers, [---] engagements


"$ARDX China has approved Tenapanor for treating hyperphosphatemia. More Info: $XBI $IBB $XPH $PPH https://pryzm.ozmosi.com/product/2151 https://pryzm.ozmosi.com/product/2151"  
[X Link](https://x.com/OzmosiHealth/status/1894727253168439735)  2025-02-26T12:32Z [----] followers, [---] engagements


"$IVA IVEVF PARIS:IVA Inventiva's study on lanifibranor treatment for MASLD/MASH patients & preclinical models published in Journal of Hepatology Reports. More Info: $XBI $IBB $XPH $PPH https://pryzm.ozmosi.com/product/19858 https://pryzm.ozmosi.com/product/19858"  
[X Link](https://x.com/OzmosiHealth/status/1940546604383326409)  2025-07-02T23:02Z [----] followers, [---] engagements


"$ABCL AbCellera releases Q2 [----] results & doses first participants in Phase [--] trial for ABCL635 treating Vasomotor Symptoms. More Info: $XBI $IBB $XPH $PPH https://pryzm.ozmosi.com/product/32498 https://pryzm.ozmosi.com/product/32498"  
[X Link](https://x.com/OzmosiHealth/status/1953554921460314396)  2025-08-07T20:32Z [----] followers, [----] engagements


"$EVAX Evaxion Biotech announced they will present Phase [--] Melanoma results on 2025-10-17 for EVX-01 More Info: https://pryzm.ozmosi.com/product/25443 https://pryzm.ozmosi.com/product/25443"  
[X Link](https://x.com/OzmosiHealth/status/1978216503305531640)  2025-10-14T21:49Z [----] followers, [---] engagements


"$XLO +4.15% today as Xilio Therapeutics to Present Phase [--] Data for Vilastobart Highlighting Response Rate in Patients with MSS mCRC and High Plasma Tumor Mutational Burden as a Late-Breaking Presentation at SITC 40th Annual Meeting More Info: https://pryzm.ozmosi.com/product/23341 https://pryzm.ozmosi.com/product/23341"  
[X Link](https://x.com/OzmosiHealth/status/1983895820417085712)  2025-10-30T13:56Z [----] followers, [---] engagements


"$XLO Xilio Therapeutics announced they will present P2 Colorectal Cancer results on 2025-11-07 for Vilastobart More Info: https://pryzm.ozmosi.com/product/23341 https://pryzm.ozmosi.com/product/23341"  
[X Link](https://x.com/OzmosiHealth/status/1985363694251884810)  2025-11-03T15:09Z [----] followers, [---] engagements


"$NRIX Nurix Therapeutics presented P1 Oncology Solid Tumor Unspecified results on 2025-11-07 for NX-1607 More Info: https://pryzm.ozmosi.com/product/24725.0 https://pryzm.ozmosi.com/product/24725.0"  
[X Link](https://x.com/OzmosiHealth/status/1987954938232684634)  2025-11-10T18:46Z [----] followers, [---] engagements


"$XLO Xilio Therapeutics presented P1 Oncology Solid Tumor Unspecified results on 2025-11-07 for Efarindodekin alfa More Info: https://pryzm.ozmosi.com/product/26196.0 https://pryzm.ozmosi.com/product/26196.0"  
[X Link](https://x.com/OzmosiHealth/status/1987954973724852667)  2025-11-10T18:46Z [----] followers, [---] engagements


"🚀🚨 BIOPHARM CATALYST ALERT 📆 $IMMP Immutep will present Phase [--] Sarcoma Data for Eftilagimod alpha (LAG3 Analogue - Fusion Protein) tomorrow 👀"  
[X Link](https://x.com/OzmosiHealth/status/1988565530450764220)  2025-11-12T11:12Z [----] followers, [---] engagements


"$CGTX -5.22% today as Cognition Therapeutics Completes Enrollment in Phase [--] Study of Zervimesine (CT1812) in Early Alzheimer's Disease More Info: https://pryzm.ozmosi.com/product/17378 https://pryzm.ozmosi.com/product/17378"  
[X Link](https://x.com/OzmosiHealth/status/1989000646322786756)  2025-11-13T16:01Z [----] followers, [---] engagements


"$HRMY +0.64% today as Harmony Biosciences Announces Positive Results From the Pivotal Bioequivalence Study for Pitolisant Gastro-Resistant Formulation More Info: https://pryzm.ozmosi.com/product/1714 https://pryzm.ozmosi.com/product/1714"  
[X Link](https://x.com/OzmosiHealth/status/1992971046954094956)  2025-11-24T14:58Z [----] followers, [---] engagements


"$CGEM -6.60% today as Cullinan Therapeutics Receives FDA Fast Track Designation for CLN-049 a Novel FLT3xCD3 T Cell Engager in Relapsed/Refractory Acute Myeloid Leukemia More Info: https://pryzm.ozmosi.com/product/24765 https://pryzm.ozmosi.com/product/24765"  
[X Link](https://x.com/OzmosiHealth/status/1995519776974659828)  2025-12-01T15:46Z [----] followers, [---] engagements


"$CGTX -5.49% today as Cognition Therapeutics Presents Phase [--] Plan for Zervimesine (CT1812) in Alzheimer's Disease at Clinical Trials on Alzheimer's Disease (CTAD) Conference More Info: https://pryzm.ozmosi.com/product/17378 https://pryzm.ozmosi.com/product/17378"  
[X Link](https://x.com/OzmosiHealth/status/1995519812844343780)  2025-12-01T15:46Z [----] followers, [---] engagements


"$VALN Valneva presented P2 Lyme Disease results on 2025-11-26 for VLA-15 More Info: https://pryzm.ozmosi.com/product/17682 https://pryzm.ozmosi.com/product/17682"  
[X Link](https://x.com/OzmosiHealth/status/1995577390865465772)  2025-12-01T19:35Z [----] followers, [---] engagements


"$BMEA -7.31% today as Biomea Fusion Announces Oral Presentation of Icovamenib at the 23rd World Congress on Insulin Resistance Diabetes & Cardiovascular Disease (WCIRDC) More Info: https://pryzm.ozmosi.com/product/23569 https://pryzm.ozmosi.com/product/23569"  
[X Link](https://x.com/OzmosiHealth/status/1995617678950535180)  2025-12-01T22:15Z [----] followers, [----] engagements


"$ABOS Acumen Pharmaceuticals presented P2 Alzheimer Disease results on 2025-12-02 for Sabirnetug More Info: https://pryzm.ozmosi.com/product/22482 https://pryzm.ozmosi.com/product/22482"  
[X Link](https://x.com/OzmosiHealth/status/1996323430111609089)  2025-12-03T20:59Z [----] followers, [---] engagements


"$BMEA Biomea Fusion presented P2 Type [--] Diabetes results on 2025-12-05 for Icovamenib More Info: https://pryzm.ozmosi.com/product/23569 https://pryzm.ozmosi.com/product/23569"  
[X Link](https://x.com/OzmosiHealth/status/1998141330975781344)  2025-12-08T21:23Z [----] followers, [---] engagements


"$DERM Journey Medical presented P1 Rosacea results on 2025-12-10 for DFD-29 More Info: https://pryzm.ozmosi.com/product/25524 https://pryzm.ozmosi.com/product/25524"  
[X Link](https://x.com/OzmosiHealth/status/1999185888710889879)  2025-12-11T18:33Z [----] followers, [---] engagements


"$TNYA -2.50% today as Tenaya Therapeutics Announces Rapid Resolution and Lifting of Clinical Hold for MyPEAK-1 Phase 1b/2a Clinical Trial of TN-201 Gene Therapy More Info: https://pryzm.ozmosi.com/product/26351 https://pryzm.ozmosi.com/product/26351"  
[X Link](https://x.com/OzmosiHealth/status/1999238032042430516)  2025-12-11T22:01Z [----] followers, [---] engagements


"$HOWL Werewolf Therapeutics announced they will present P1 Oncology Solid Tumor Unspecified results in 1H26 for WTX-124 More Info: https://pryzm.ozmosi.com/product/25073 https://pryzm.ozmosi.com/product/25073"  
[X Link](https://x.com/OzmosiHealth/status/2002094801206890922)  2025-12-19T19:12Z [----] followers, [---] engagements


"$INCY Incyte Announces Positive Topline Results from Pivotal Study of Tafasitamab (Monjuvi/Minjuvi) as a First-line Treatment for Diffuse Large B-Cell Lymphoma More Info: https://pryzm.ozmosi.com/product/18517 https://pryzm.ozmosi.com/product/18517"  
[X Link](https://x.com/OzmosiHealth/status/2008177430738153976)  2026-01-05T14:03Z [----] followers, [---] engagements


"$COYA Coya Therapeutics Announces U.S. FDA Acceptance of Investigational New Drug (IND) Application for COYA [---] for the Treatment of Frontotemporal Dementia (FTD) More Info: https://pryzm.ozmosi.com/product/31651 https://pryzm.ozmosi.com/product/31651"  
[X Link](https://x.com/OzmosiHealth/status/2008177437641986302)  2026-01-05T14:03Z [----] followers, [---] engagements


"$APGE Apogee Therapeutics Announces Positive Interim Results from Phase 1b Trial of Zumilokibart (APG777) its Potentially Best-in-Class Anti-IL-13 Antibody in Patients with Mild-to-Moderate Asthma and Highlights [----] Anticipated Milestones and Outlook More Info: https://pryzm.ozmosi.com/product/31038 https://pryzm.ozmosi.com/product/31038"  
[X Link](https://x.com/OzmosiHealth/status/2008539735644598329)  2026-01-06T14:02Z [----] followers, [---] engagements


"$AKBA Akebia Therapeutics Announces First Patient Dosed in Phase [--] Clinical Trial of Praliciguat for the Treatment of Focal Segmental Glomerulosclerosis (FSGS) More Info: https://pryzm.ozmosi.com/product/19874 https://pryzm.ozmosi.com/product/19874"  
[X Link](https://x.com/OzmosiHealth/status/2008539749674611001)  2026-01-06T14:02Z [----] followers, [---] engagements


"$EXEL +3.09% today Exelixis and Natera to Collaborate on STELLAR-316 a Phase [--] Pivotal Trial of Zanzalintinib for Patients with Colorectal Cancer More Info: https://pryzm.ozmosi.com/product/19713 https://pryzm.ozmosi.com/product/19713"  
[X Link](https://x.com/OzmosiHealth/status/2008902168749953421)  2026-01-07T14:02Z [----] followers, [---] engagements


"$GNLX Genelux announced they will present P3 Ovarian Cancer results in 2H26 for Olvimulogene nanivacirepvec More Info: https://pryzm.ozmosi.com/product/21639 https://pryzm.ozmosi.com/product/21639"  
[X Link](https://x.com/OzmosiHealth/status/2008930697730523175)  2026-01-07T15:56Z [----] followers, [---] engagements


"$JBIO Jade Biosciences announced they will present P2 IgA Nephropathy results in YE27 for JADE-101 More Info: https://pryzm.ozmosi.com/product/34694 https://pryzm.ozmosi.com/product/34694"  
[X Link](https://x.com/OzmosiHealth/status/2008930703547977814)  2026-01-07T15:56Z [----] followers, [---] engagements


"$VRDN Viridian Therapeutics announced they will present P1 Healthy Volunteers results in 2H26 for VRDN-008 More Info: https://pryzm.ozmosi.com/product/32196 https://pryzm.ozmosi.com/product/32196"  
[X Link](https://x.com/OzmosiHealth/status/2008966943697469934)  2026-01-07T18:20Z [----] followers, [---] engagements


"$VRDN Viridian Therapeutics announced they will present P3 Thyroid Eye Disease results in 1Q26 for Elegrobart More Info: https://pryzm.ozmosi.com/product/25782 https://pryzm.ozmosi.com/product/25782"  
[X Link](https://x.com/OzmosiHealth/status/2008966946851569811)  2026-01-07T18:20Z [----] followers, [---] engagements


"$CGTX Cognition presented P2 Lewy Body Dementia results on 2026-01-06 for Zervimesine More Info: https://pryzm.ozmosi.com/product/17378 https://pryzm.ozmosi.com/product/17378"  
[X Link](https://x.com/OzmosiHealth/status/2008966970700423256)  2026-01-07T18:20Z [----] followers, [---] engagements


"$RNAZ TRANSCODE THERAPEUTICS presented P0 Glioblastoma results on 2026-01-06 for TTX-MC138 More Info: https://pryzm.ozmosi.com/product/26544 https://pryzm.ozmosi.com/product/26544"  
[X Link](https://x.com/OzmosiHealth/status/2008966987678986751)  2026-01-07T18:20Z [----] followers, [---] engagements


"$RANI Rani Therapeutics Initiates Phase [--] Study of RT-114 RaniPill for the Treatment of Obesity in Collaboration with ProGen More Info: https://pryzm.ozmosi.com/product/33131 https://pryzm.ozmosi.com/product/33131"  
[X Link](https://x.com/OzmosiHealth/status/2009264511946309675)  2026-01-08T14:02Z [----] followers, [---] engagements


"$INKT MiNK Therapeutics and University of WisconsinMadison Announce Phase [--] Clinical Trial of Allo-iNKT Cell Therapy (AgenT-797) to Evaluate Prevention of Graft-Versus-Host Disease More Info: https://pryzm.ozmosi.com/product/23546 https://pryzm.ozmosi.com/product/23546"  
[X Link](https://x.com/OzmosiHealth/status/2009309708633649591)  2026-01-08T17:02Z [----] followers, [---] engagements


"$ALXO ALX Oncology announced they will present P1 Esophageal CancerNon-Small-Cell Lung CancerHead and Neck CancerColorectal CancerSquamous Cell Carcinoma results in 1H26 for ALX-2004 More Info: https://pryzm.ozmosi.com/product/34788 https://pryzm.ozmosi.com/product/34788"  
[X Link](https://x.com/OzmosiHealth/status/2009691742099108246)  2026-01-09T18:20Z [----] followers, [---] engagements


"$ALXO ALX Oncology announced they will present P2 Breast Cancer results in 3Q26 for Evorpacept More Info: https://pryzm.ozmosi.com/product/17751 https://pryzm.ozmosi.com/product/17751"  
[X Link](https://x.com/OzmosiHealth/status/2009691744649261275)  2026-01-09T18:20Z [----] followers, [---] engagements


"$ATAI ATAI Life Sciences announced they will present P2 Depressive Disorder Treatment-Resistant results in 2H26 for VLS-01 More Info: https://pryzm.ozmosi.com/product/25732 https://pryzm.ozmosi.com/product/25732"  
[X Link](https://x.com/OzmosiHealth/status/2009691747149066731)  2026-01-09T18:20Z [----] followers, [---] engagements


"$ATAI ATAI Life Sciences announced they will present P2 Depressive Disorder Treatment-Resistant results in 4Q26 for BPL-003 More Info: https://pryzm.ozmosi.com/product/25522 https://pryzm.ozmosi.com/product/25522"  
[X Link](https://x.com/OzmosiHealth/status/2009691749573362093)  2026-01-09T18:20Z [----] followers, [---] engagements


"$CGEM Cullinan Oncology announced they will present P1 Myelodysplastic Syndrome results in 2H26 for CLN-049 More Info: https://pryzm.ozmosi.com/product/24765 https://pryzm.ozmosi.com/product/24765"  
[X Link](https://x.com/OzmosiHealth/status/2009691774097457305)  2026-01-09T18:20Z [----] followers, [---] engagements


"$ELVN Enliven Therapeutics presented P1 Chronic Myeloid Leukemia results on 2026-01-08 for ELVN-001 More Info: https://pryzm.ozmosi.com/product/25409 https://pryzm.ozmosi.com/product/25409"  
[X Link](https://x.com/OzmosiHealth/status/2009691830393434320)  2026-01-09T18:20Z [----] followers, [---] engagements


"$CABA IND Amendment Clearance Obtained for Clinical Manufacturing of Rese-Cel from Cabaletta Bio Using Cellares' Automated Platforms More Info: https://pryzm.ozmosi.com/product/27425 https://pryzm.ozmosi.com/product/27425"  
[X Link](https://x.com/OzmosiHealth/status/2010714116193911221)  2026-01-12T14:02Z [----] followers, [---] engagements


"$CGON CG Oncology announced they will present P3 Muscle CancerBladder Cancer results in 1H26 for Cretostimogene grenadenorepvec More Info: https://pryzm.ozmosi.com/product/17148 https://pryzm.ozmosi.com/product/17148"  
[X Link](https://x.com/OzmosiHealth/status/2010812148201767311)  2026-01-12T20:32Z [----] followers, [---] engagements


"$INSM Insmed announced they will present P2 Hidradenitis Suppurativa results in 2Q26 for Brensocatib More Info: https://pryzm.ozmosi.com/product/14505 https://pryzm.ozmosi.com/product/14505"  
[X Link](https://x.com/OzmosiHealth/status/2010812162391019821)  2026-01-12T20:32Z [----] followers, [---] engagements


"$KTTA +nan% today Pasithea Therapeutics Provides Outlook on PAS-004 Clinical Programs and Data Release Timelines More Info: https://pryzm.ozmosi.com/product/25828 https://pryzm.ozmosi.com/product/25828"  
[X Link](https://x.com/OzmosiHealth/status/2011076361830437308)  2026-01-13T14:02Z [----] followers, [---] engagements


"$INAB IN8bio presented P1 Glioblastoma results on 2026-01-12 for INB-200 More Info: https://pryzm.ozmosi.com/product/26008 https://pryzm.ozmosi.com/product/26008"  
[X Link](https://x.com/OzmosiHealth/status/2011141272535478569)  2026-01-13T18:20Z [----] followers, [---] engagements


"$INAB IN8bio presented P2 Glioblastoma results on 2026-01-12 for INB-400 More Info: https://pryzm.ozmosi.com/product/26928 https://pryzm.ozmosi.com/product/26928"  
[X Link](https://x.com/OzmosiHealth/status/2011141275962228743)  2026-01-13T18:20Z [----] followers, [---] engagements


"$ORKA Oruka Therapeutics presented P1 Healthy Volunteers results on 2026-01-12 for ORKA-002 More Info: https://pryzm.ozmosi.com/product/34383 https://pryzm.ozmosi.com/product/34383"  
[X Link](https://x.com/OzmosiHealth/status/2011141288872271877)  2026-01-13T18:20Z [----] followers, [---] engagements


"$CCCC C4 Therapeutics Outlines Strategic Milestones to Advance Cemsidomide as a Potential Best-in-Class IKZF1/3 Degrader and Discovery Strategy Focused on Novel Targets in Clinically Validated Pathways More Info: https://pryzm.ozmosi.com/product/21073 https://pryzm.ozmosi.com/product/21073"  
[X Link](https://x.com/OzmosiHealth/status/2011438698605445164)  2026-01-14T14:02Z [----] followers, [---] engagements


"$KTTA Pasithea Therapeutics announced they will present P1 Neurofibroma Plexiform results in 2H26 for PAS-004 More Info: https://pryzm.ozmosi.com/product/25828 https://pryzm.ozmosi.com/product/25828"  
[X Link](https://x.com/OzmosiHealth/status/2011503632571908145)  2026-01-14T18:20Z [----] followers, [---] engagements


"$CCCC C4 Therapeutics announced they will present P2 Multiple Myeloma results in 2H27 for Cemsidomide More Info: https://pryzm.ozmosi.com/product/21073 https://pryzm.ozmosi.com/product/21073"  
[X Link](https://x.com/OzmosiHealth/status/2011865984848838712)  2026-01-15T18:20Z [----] followers, [---] engagements


"$NBIX Neurocrine presented P2 Tardive Dyskinesia results on 2026-01-15 for Valbenazine More Info: https://pryzm.ozmosi.com/product/2327 https://pryzm.ozmosi.com/product/2327"  
[X Link](https://x.com/OzmosiHealth/status/2012228369782583797)  2026-01-16T18:20Z [----] followers, [---] engagements


"$DYN Dyne Therapeutics Receives Orphan Drug Designation in Japan for Zeleciment Basivarsen (DYNE-101) for Myotonic Dystrophy Type [--] More Info: https://pryzm.ozmosi.com/product/26167 https://pryzm.ozmosi.com/product/26167"  
[X Link](https://x.com/OzmosiHealth/status/2013613179210018829)  2026-01-20T14:02Z [----] followers, [---] engagements


"$LTRN Lantern Pharma's LP-284 Receives FDA Orphan Drug Designation for Soft Tissue Sarcomas More Info: https://pryzm.ozmosi.com/product/26464 https://pryzm.ozmosi.com/product/26464"  
[X Link](https://x.com/OzmosiHealth/status/2013613183030927625)  2026-01-20T14:02Z [----] followers, [---] engagements


"$NSRX Nasus Pharma Announces Positive Interim Results from Phase [--] Clinical Study of NS002 Intranasal Epinephrine Powder More Info: https://pryzm.ozmosi.com/product/36910 https://pryzm.ozmosi.com/product/36910"  
[X Link](https://x.com/OzmosiHealth/status/2013613186747113598)  2026-01-20T14:02Z [----] followers, [---] engagements


"$IVVD Invivyd and SPEAR Study Group Announce Plan for Phase [--] Study of VYD2311 for Treatment of Long COVID and COVID Vaccine-Injured Individuals to Commence Mid-2026 More Info: https://pryzm.ozmosi.com/product/33169 https://pryzm.ozmosi.com/product/33169"  
[X Link](https://x.com/OzmosiHealth/status/2013613221094269404)  2026-01-20T14:02Z [----] followers, [---] engagements


"$ACTU Actuate Therapeutics Announces Plans to Expand Clinical Pipeline Advancing Elraglusib Tablet into a Phase 1/2 Clinical Program in Refractory Cancers More Info: https://pryzm.ozmosi.com/product/22019 https://pryzm.ozmosi.com/product/22019"  
[X Link](https://x.com/OzmosiHealth/status/2013975502382633267)  2026-01-21T14:02Z [----] followers, [---] engagements


"$GMAB Genmab Announces Net Sales of DARZALEX (daratumumab) for [----] More Info: https://pryzm.ozmosi.com/product/3879 https://pryzm.ozmosi.com/product/3879"  
[X Link](https://x.com/OzmosiHealth/status/2013975505012421053)  2026-01-21T14:02Z [----] followers, [---] engagements


"$NSRX Nasus Pharma presented P2 Anaphylaxis results on 2026-01-20 for FMXIN-002 More Info: https://pryzm.ozmosi.com/product/36910 https://pryzm.ozmosi.com/product/36910"  
[X Link](https://x.com/OzmosiHealth/status/2014040366257955046)  2026-01-21T18:20Z [----] followers, [---] engagements


"$NERV Minerva Neurosciences to Host Virtual KOL Event to Discuss Roluperidone: From Unmet Need to Reality Potentially the First Treatment for Patients with Negative Symptoms of Schizophrenia on February [--] [----] More Info: https://pryzm.ozmosi.com/product/16270 https://pryzm.ozmosi.com/product/16270"  
[X Link](https://x.com/OzmosiHealth/status/2015787486384185662)  2026-01-26T14:02Z [----] followers, [---] engagements


"$TGTX TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI (ublituximab) in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum More Info: https://pryzm.ozmosi.com/product/8349 https://pryzm.ozmosi.com/product/8349"  
[X Link](https://x.com/OzmosiHealth/status/2016149829421039952)  2026-01-27T14:02Z [----] followers, [---] engagements


"$SRPT Sarepta presented P3 Muscular Dystrophy Duchenne results on 2026-01-26 for Delandistrogene moxeparvovec More Info: https://pryzm.ozmosi.com/product/25071 https://pryzm.ozmosi.com/product/25071"  
[X Link](https://x.com/OzmosiHealth/status/2016214660245291452)  2026-01-27T18:20Z [----] followers, [---] engagements


"$BIIB Biogen's Litifilimab Receives FDA Breakthrough Therapy Designation for Cutaneous Lupus Erythematosus a Disease With No Targeted Treatment Options More Info: https://pryzm.ozmosi.com/product/17141 https://pryzm.ozmosi.com/product/17141"  
[X Link](https://x.com/OzmosiHealth/status/2016512174957724089)  2026-01-28T14:02Z [----] followers, [---] engagements


"$IMMX Immix Biopharma Receives U.S. FDA Breakthrough Therapy Designation for NXC-201 More Info: https://pryzm.ozmosi.com/product/28115 https://pryzm.ozmosi.com/product/28115"  
[X Link](https://x.com/OzmosiHealth/status/2016512190829015051)  2026-01-28T14:02Z [----] followers, [---] engagements


"$TGTX TG Therapeutics announced they will present P2 Multiple Sclerosis results on 2026-02-05 for Ublituximab More Info: https://pryzm.ozmosi.com/product/8349 https://pryzm.ozmosi.com/product/8349"  
[X Link](https://x.com/OzmosiHealth/status/2016577041353888083)  2026-01-28T18:20Z [----] followers, [----] engagements


"$CRDF Cardiff Oncology presented P2 Colorectal Cancer results on 2026-01-27 for FOLFOX More Info: https://pryzm.ozmosi.com/product/19487 https://pryzm.ozmosi.com/product/19487"  
[X Link](https://x.com/OzmosiHealth/status/2016577050623299655)  2026-01-28T18:20Z [----] followers, [---] engagements


"$OSE OSE Immunotherapeutics Selects Chronic Pouchitis and Hidradenitis Suppurativa as New Key Indications for Lusvertikimab More Info: https://pryzm.ozmosi.com/product/19380 https://pryzm.ozmosi.com/product/19380"  
[X Link](https://x.com/OzmosiHealth/status/2016874650698195412)  2026-01-29T14:02Z [----] followers, [---] engagements


"$PDSB PDS Biotech presented P2 Prostate Cancer results on 2026-01-28 for PDS-0101 More Info: https://pryzm.ozmosi.com/product/24532 https://pryzm.ozmosi.com/product/24532"  
[X Link](https://x.com/OzmosiHealth/status/2016939423334801635)  2026-01-29T18:20Z [----] followers, [---] engagements


"$IMMP Immutep announced they will present P1 Autoimmune Disease Unspecified results in 1H26 for IMP-761 More Info: https://pryzm.ozmosi.com/product/25134 https://pryzm.ozmosi.com/product/25134"  
[X Link](https://x.com/OzmosiHealth/status/2017301818347557221)  2026-01-30T18:20Z [----] followers, [---] engagements


"$IMMP Immutep announced they will present P3 Non-Small-Cell Lung Cancer results in 1Q26 for Eftilagimod alpha More Info: https://pryzm.ozmosi.com/product/14597 https://pryzm.ozmosi.com/product/14597"  
[X Link](https://x.com/OzmosiHealth/status/2017301821254210009)  2026-01-30T18:20Z [----] followers, [---] engagements


"$WVE -0.46% today Wave Life Sciences Announces Plans to Accelerate Regulatory Engagement with Full Control of WVE-006 for Alpha-1 Antitrypsin Deficiency More Info: https://pryzm.ozmosi.com/product/27387 https://pryzm.ozmosi.com/product/27387"  
[X Link](https://x.com/OzmosiHealth/status/2018324104810823821)  2026-02-02T14:02Z [----] followers, [---] engagements


"$GDRX -5.60% today [--] Degrees Pharmaceuticals Expands Access to ARAKODA with GoodRx Partnership More Info: https://pryzm.ozmosi.com/product/2090 https://pryzm.ozmosi.com/product/2090"  
[X Link](https://x.com/OzmosiHealth/status/2018324110091464899)  2026-02-02T14:02Z [----] followers, [---] engagements


"$IGC -0.53% today IGC Pharma Reaches 70% Enrollment in Phase [--] CALMA Trial Evaluating IGC-AD1 for Alzheimer's Agitation More Info: https://pryzm.ozmosi.com/product/25988 https://pryzm.ozmosi.com/product/25988"  
[X Link](https://x.com/OzmosiHealth/status/2018324113182597313)  2026-02-02T14:02Z [----] followers, [---] engagements


"$MLTX -3.27% today MoonLake Announces FDA Fast Track Designation for Sonelokimab Palmoplantar Pustulosis (PPP) and Provides Details on Upcoming Investor Day More Info: https://pryzm.ozmosi.com/product/20826 https://pryzm.ozmosi.com/product/20826"  
[X Link](https://x.com/OzmosiHealth/status/2018324118882627881)  2026-02-02T14:02Z [----] followers, [---] engagements


"$EXEL -2.14% today Exelixis Announces U.S. FDA Accepted the New Drug Application for Zanzalintinib in Combination with an Immune Checkpoint Inhibitor for Patients with Metastatic Colorectal Cancer More Info: https://pryzm.ozmosi.com/product/19713 https://pryzm.ozmosi.com/product/19713"  
[X Link](https://x.com/OzmosiHealth/status/2018324133520769248)  2026-02-02T14:02Z [----] followers, [---] engagements


"$PHRM PharmaTher Launches Strategic Initiative to Pursue Health Canada Approval for Generic Semaglutide in Canada Building on FDA-Approved Ketamine Success More Info: https://pryzm.ozmosi.com/product/1987 https://pryzm.ozmosi.com/product/1987"  
[X Link](https://x.com/OzmosiHealth/status/2018339251214336130)  2026-02-02T15:02Z [----] followers, [---] engagements


"$RLAY +6.19% today Relay Therapeutics Announces Zovegalisib Granted Breakthrough Therapy Designation by U.S. FDA for PIK3CA-mutant HR+/HER2- Advanced Breast Cancer More Info: https://pryzm.ozmosi.com/product/25143 https://pryzm.ozmosi.com/product/25143"  
[X Link](https://x.com/OzmosiHealth/status/2018686559432880191)  2026-02-03T14:02Z [----] followers, [---] engagements


"$TOVX -0.11% today Theriva Biologics Announces Upcoming Presentation of Data from VCN-01 Retinoblastoma Phase [--] Clinical Trial at APAO [----] More Info: https://pryzm.ozmosi.com/product/16795 https://pryzm.ozmosi.com/product/16795"  
[X Link](https://x.com/OzmosiHealth/status/2018686567423090791)  2026-02-03T14:02Z [----] followers, [---] engagements


"$RARE +3.08% today Ultragenyx Announces Positive Longer-Term Data Demonstrating Treatment with UX111 Gene Therapy Results in Sustained Significant Reductions in CSF-HS and Continued Meaningful Improvements in Clinical Function Across Multiple Developmental Domains in Children with Sanfilippo Syndrome (MPS IIIA) More Info: https://pryzm.ozmosi.com/product/22121 https://pryzm.ozmosi.com/product/22121"  
[X Link](https://x.com/OzmosiHealth/status/2018686576155586600)  2026-02-03T14:02Z [----] followers, [--] engagements


"$ABBV +1.22% today AbbVie Submits Regulatory Applications to FDA and EMA for Upadacitinib (RINVOQ) in Adults and Adolescents With Vitiligo More Info: https://pryzm.ozmosi.com/product/13169 https://pryzm.ozmosi.com/product/13169"  
[X Link](https://x.com/OzmosiHealth/status/2018686593977274803)  2026-02-03T14:02Z [----] followers, [---] engagements


"$IMUX Immunic to Present Additional Phase [--] CALLIPER Trial Data for Vidofludimus Calcium at the ACTRIMS Forum [----] Reinforcing Its Potential in Progressive Multiple Sclerosis More Info: https://pryzm.ozmosi.com/product/8436 https://pryzm.ozmosi.com/product/8436"  
[X Link](https://x.com/OzmosiHealth/status/2019048967204704264)  2026-02-04T14:02Z [----] followers, [---] engagements


"$BIIB Nature Medicine Publishes Results from the Pivotal DEVOTE Study of High-Dose Regimen of Nusinersen in Spinal Muscular Atrophy More Info: https://pryzm.ozmosi.com/product/1525 https://pryzm.ozmosi.com/product/1525"  
[X Link](https://x.com/OzmosiHealth/status/2019048969738076410)  2026-02-04T14:02Z [----] followers, [---] engagements


"$TEVA Teva Canada Announces Approval of Expanded Indication of PrAJOVY (fremanezumab solution for subcutaneous injection) the First Anti-CGRP Preventive Treatment for Pediatric Episodic Migraine More Info: https://pryzm.ozmosi.com/product/10812 https://pryzm.ozmosi.com/product/10812"  
[X Link](https://x.com/OzmosiHealth/status/2019048972984496131)  2026-02-04T14:02Z [----] followers, [---] engagements


"$RLAY Relay Therapeutics announced they will present P3 Breast Cancer results on 2026-03-16 for Zovegalisib More Info: https://pryzm.ozmosi.com/product/25143 https://pryzm.ozmosi.com/product/25143"  
[X Link](https://x.com/OzmosiHealth/status/2019113766219313452)  2026-02-04T18:20Z [----] followers, [---] engagements


"$RARE Ultragenyx presented Unknown Mucopolysaccharidosis III results on 2026-02-03 for Rebisufligene etisparvovec More Info: https://pryzm.ozmosi.com/product/22121 https://pryzm.ozmosi.com/product/22121"  
[X Link](https://x.com/OzmosiHealth/status/2019113779192291466)  2026-02-04T18:20Z [----] followers, [---] engagements


"$RNAZ TransCode Therapeutics and Quantum Leap Announce Submission of IND Amendment for Phase 2a Clinical Trial with TTX-MC138 More Info: https://pryzm.ozmosi.com/product/26544 https://pryzm.ozmosi.com/product/26544"  
[X Link](https://x.com/OzmosiHealth/status/2019411354554384477)  2026-02-05T14:02Z [----] followers, [---] engagements


"$FBLG FibroBiologics Announces Issuance of Canadian Patent Covering Novel Fibroblast-Based Treatment for Cachexia More Info: https://pryzm.ozmosi.com/product/19067 https://pryzm.ozmosi.com/product/19067"  
[X Link](https://x.com/OzmosiHealth/status/2019411357632975017)  2026-02-05T14:02Z [----] followers, [---] engagements


"$ATOS Atossa Therapeutics Maintains Strong Market Position for (Z)-Endoxifen for Duchenne Muscular Dystrophy as Congress Reauthorizes Priority Review Voucher Program More Info: https://pryzm.ozmosi.com/product/32506 https://pryzm.ozmosi.com/product/32506"  
[X Link](https://x.com/OzmosiHealth/status/2019411360405418429)  2026-02-05T14:02Z [----] followers, [---] engagements


"$ALVO Alvotech Announces Positive Top-Line Results from Pivotal Pharmacokinetic Study for Proposed Biosimilar to Entyvio More Info: https://pryzm.ozmosi.com/product/8410 https://pryzm.ozmosi.com/product/8410"  
[X Link](https://x.com/OzmosiHealth/status/2019411363202998700)  2026-02-05T14:02Z [----] followers, [---] engagements


"$MIRM Mirum Pharmaceuticals Announces Health Canada Authorization of LIVMARLI for the Treatment of Cholestatic Pruritus in Patients with Progressive Familial Intrahepatic Cholestasis (PFIC) More Info: https://pryzm.ozmosi.com/product/5770 https://pryzm.ozmosi.com/product/5770"  
[X Link](https://x.com/OzmosiHealth/status/2019411368978575831)  2026-02-05T14:02Z [----] followers, [--] engagements


"$MIRM Mirum Pharmaceuticals Announces Health Canada Authorization of LIVMARLI for the Treatment of Cholestatic Pruritus in Patients with Progressive Familial Intrahepatic Cholestasis (PFIC) More Info: https://pryzm.ozmosi.com/product/5770 https://pryzm.ozmosi.com/product/5770"  
[X Link](https://x.com/OzmosiHealth/status/2019411371469992110)  2026-02-05T14:02Z [----] followers, [---] engagements


"$MIRM Mirum Pharmaceuticals Announces Health Canada Authorization of LIVMARLI Tablet Formulation for the Treatment of Cholestatic Pruritus in Patients with Alagille Syndrome More Info: https://pryzm.ozmosi.com/product/5770 https://pryzm.ozmosi.com/product/5770"  
[X Link](https://x.com/OzmosiHealth/status/2019411374095626458)  2026-02-05T14:02Z [----] followers, [---] engagements


"$MIRM Mirum Pharmaceuticals Announces Health Canada Authorization of LIVMARLI Tablet Formulation for the Treatment of Cholestatic Pruritus in Patients with Alagille Syndrome More Info: https://pryzm.ozmosi.com/product/5770 https://pryzm.ozmosi.com/product/5770"  
[X Link](https://x.com/OzmosiHealth/status/2019411377400774687)  2026-02-05T14:02Z [----] followers, [---] engagements


"$MRK Merck Announces Health Canada Approval of ENFLONSIA for the prevention of RSV in newborns and infants More Info: https://pryzm.ozmosi.com/product/19724 https://pryzm.ozmosi.com/product/19724"  
[X Link](https://x.com/OzmosiHealth/status/2019411380433260695)  2026-02-05T14:02Z [----] followers, [---] engagements


"$HIMS +10.12% today Hims & Hers Expands Personalized Weight Loss Portfolio with Access to Compounded Semaglutide Pills Starting at $49/Month* More Info: https://pryzm.ozmosi.com/product/1987 https://pryzm.ozmosi.com/product/1987"  
[X Link](https://x.com/OzmosiHealth/status/2019426332057432259)  2026-02-05T15:02Z [----] followers, [---] engagements


"$CERO CERo Therapeutics announced they will present P1 Acute Myeloid Leukemia results on 2026-02-05 for CER-1236 More Info: https://pryzm.ozmosi.com/product/30722 https://pryzm.ozmosi.com/product/30722"  
[X Link](https://x.com/OzmosiHealth/status/2019476140705083630)  2026-02-05T18:20Z [----] followers, [--] engagements


"$IMUX Immunic announced they will present P2 Multiple Sclerosis Progressive results on 2026-02-05 for Vidofludimus More Info: https://pryzm.ozmosi.com/product/8436 https://pryzm.ozmosi.com/product/8436"  
[X Link](https://x.com/OzmosiHealth/status/2019476150003929508)  2026-02-05T18:20Z [----] followers, [---] engagements


"$KOD Kodiak Sciences announced they will present P1 Macular Edema results on 2026-02-07 for Tabirafusp alfa More Info: https://pryzm.ozmosi.com/product/34569 https://pryzm.ozmosi.com/product/34569"  
[X Link](https://x.com/OzmosiHealth/status/2019476152591757722)  2026-02-05T18:20Z [----] followers, [---] engagements


"$VSTM Verastem announced they will present P1 Non-Small-Cell Lung CancerPancreatic Ductal CarcinomaColorectal Cancer results in 1H26 for VS-7375 More Info: https://pryzm.ozmosi.com/product/32027 https://pryzm.ozmosi.com/product/32027"  
[X Link](https://x.com/OzmosiHealth/status/2019476155255107953)  2026-02-05T18:20Z [----] followers, [---] engagements


"$VSTM Verastem announced they will present P2 Pancreatic Ductal Carcinoma results in 2Q26 for Avutometinib More Info: https://pryzm.ozmosi.com/product/21724 https://pryzm.ozmosi.com/product/21724"  
[X Link](https://x.com/OzmosiHealth/status/2019476157964644853)  2026-02-05T18:20Z [----] followers, [---] engagements


"$VSTM Verastem announced they will present P2 Pancreatic Ductal Carcinoma results in 2Q26 for Defactinib More Info: https://pryzm.ozmosi.com/product/562 https://pryzm.ozmosi.com/product/562"  
[X Link](https://x.com/OzmosiHealth/status/2019476160548335937)  2026-02-05T18:20Z [----] followers, [---] engagements


"$ROIV Roivant Announces Positive Phase [--] Results for Brepocitinib in Cutaneous Sarcoidosis (CS) and Reports Financial Results for the Third Quarter Ended December [--] [----] More Info: https://pryzm.ozmosi.com/product/19843 https://pryzm.ozmosi.com/product/19843"  
[X Link](https://x.com/OzmosiHealth/status/2019773634953560517)  2026-02-06T14:02Z [----] followers, [---] engagements


"$ROIV Roivant Announces Positive Phase [--] Results for Brepocitinib in Cutaneous Sarcoidosis (CS) and Reports Financial Results for the Third Quarter Ended December [--] [----] More Info: https://pryzm.ozmosi.com/product/19843 https://pryzm.ozmosi.com/product/19843"  
[X Link](https://x.com/OzmosiHealth/status/2019773637650452497)  2026-02-06T14:02Z [----] followers, [---] engagements


"$ROIV Priovant Announces Positive Phase [--] Results for Brepocitinib in Cutaneous Sarcoidosis (CS) More Info: https://pryzm.ozmosi.com/product/19843 https://pryzm.ozmosi.com/product/19843"  
[X Link](https://x.com/OzmosiHealth/status/2019773640724959238)  2026-02-06T14:02Z [----] followers, [---] engagements


"$ROIV Priovant Announces Positive Phase [--] Results for Brepocitinib in Cutaneous Sarcoidosis (CS) More Info: https://pryzm.ozmosi.com/product/19843 https://pryzm.ozmosi.com/product/19843"  
[X Link](https://x.com/OzmosiHealth/status/2019773643497361832)  2026-02-06T14:02Z [----] followers, [---] engagements


"$TGTX TG Therapeutics Announces Presentation of Data for BRIUMVI (ublituximab) in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum More Info: https://pryzm.ozmosi.com/product/8349 https://pryzm.ozmosi.com/product/8349"  
[X Link](https://x.com/OzmosiHealth/status/2019773646823399805)  2026-02-06T14:02Z [----] followers, [---] engagements


"$GILD FDA Approves Label Update for Kite's Yescarta for Relapsed/Refractory Primary Central Nervous System Lymphoma More Info: https://pryzm.ozmosi.com/product/15391 https://pryzm.ozmosi.com/product/15391"  
[X Link](https://x.com/OzmosiHealth/status/2019773650057245068)  2026-02-06T14:02Z [----] followers, [---] engagements


"$PFE FDA Grants Priority Review for HYMPAVZI (marstacimab) sBLA for the Treatment of Two Hemophilia A or B Patient Populations with Significant Medical Need More Info: https://pryzm.ozmosi.com/product/15024 https://pryzm.ozmosi.com/product/15024"  
[X Link](https://x.com/OzmosiHealth/status/2019773652917735445)  2026-02-06T14:02Z [----] followers, [---] engagements


"$BRCTF Sales of Leqembi totaled [----] billion yen in the fourth quarter [----] More Info: https://pryzm.ozmosi.com/product/16901 https://pryzm.ozmosi.com/product/16901"  
[X Link](https://x.com/OzmosiHealth/status/2019773658865324134)  2026-02-06T14:02Z [----] followers, [---] engagements


"$AIM AIM presented P2 Pancreatic Cancer results on 2026-02-05 for Rintatolimod More Info: https://pryzm.ozmosi.com/product/7277 https://pryzm.ozmosi.com/product/7277"  
[X Link](https://x.com/OzmosiHealth/status/2019838528339996804)  2026-02-06T18:20Z [----] followers, [---] engagements


"$ASND Pendopharm Announces the Approval of Yorvipath (palopegteriparatide injection) for the Treatment of Chronic Hypoparathyroidism in Adults More Info: https://pryzm.ozmosi.com/product/32243 https://pryzm.ozmosi.com/product/32243"  
[X Link](https://x.com/OzmosiHealth/status/2019879317438885953)  2026-02-06T21:02Z [----] followers, [---] engagements


"$RHHBY Roche's fenebrutinib is the first investigational medicine in over a decade that reduces disability progression in primary progressive multiple sclerosis (PPMS) More Info: https://pryzm.ozmosi.com/product/12578 https://pryzm.ozmosi.com/product/12578"  
[X Link](https://x.com/OzmosiHealth/status/2020241731007246709)  2026-02-07T21:02Z [----] followers, [---] engagements


"$RHHBY Roche's fenebrutinib is the first investigational medicine in over a decade that reduces disability progression in primary progressive multiple sclerosis (PPMS) More Info: https://pryzm.ozmosi.com/product/12578 https://pryzm.ozmosi.com/product/12578"  
[X Link](https://x.com/OzmosiHealth/status/2020241733620314466)  2026-02-07T21:02Z [----] followers, [---] engagements


"$RHHBY Genentech's Fenebrutinib Is the First Investigational Medicine in Over a Decade That Reduces Disability Progression in Primary Progressive Multiple Sclerosis (PPMS) More Info: https://pryzm.ozmosi.com/product/12578 https://pryzm.ozmosi.com/product/12578"  
[X Link](https://x.com/OzmosiHealth/status/2020241736124313934)  2026-02-07T21:02Z [----] followers, [---] engagements


"$RHHBY Genentech's Fenebrutinib Is the First Investigational Medicine in Over a Decade That Reduces Disability Progression in Primary Progressive Multiple Sclerosis (PPMS) More Info: https://pryzm.ozmosi.com/product/12578 https://pryzm.ozmosi.com/product/12578"  
[X Link](https://x.com/OzmosiHealth/status/2020241738401820842)  2026-02-07T21:02Z [----] followers, [---] engagements


"$FDMT 4DMT Completes Enrollment for 4FRONT-1 Phase [--] Clinical Trial of 4D-150 in Wet AMD More Info: https://pryzm.ozmosi.com/product/27134 https://pryzm.ozmosi.com/product/27134"  
[X Link](https://x.com/OzmosiHealth/status/2020860946735087952)  2026-02-09T14:02Z [----] followers, [--] engagements


"$KRYS Krystal Biotech Announces RMAT Designation Granted by FDA to KB707 for the Treatment of Advanced or Metastatic Non-Small Cell Lung Cancer More Info: https://pryzm.ozmosi.com/product/30849 https://pryzm.ozmosi.com/product/30849"  
[X Link](https://x.com/OzmosiHealth/status/2020860955035566193)  2026-02-09T14:02Z [----] followers, [---] engagements


"$CANF Can-Fite: Receives Canadian Patent Allowance for Namodenoson as an Anti-Obesity Therapy More Info: https://pryzm.ozmosi.com/product/19867 https://pryzm.ozmosi.com/product/19867"  
[X Link](https://x.com/OzmosiHealth/status/2020860958172946796)  2026-02-09T14:02Z [----] followers, [--] engagements


"$ESLA Estrella Immunopharma Presents Promising Updated Data on EB103 in Oral Presentation at the [----] Tandem Meetings of ASTCT & CIBMTR More Info: https://pryzm.ozmosi.com/product/29687 https://pryzm.ozmosi.com/product/29687"  
[X Link](https://x.com/OzmosiHealth/status/2020860966171521503)  2026-02-09T14:02Z [----] followers, [---] engagements


"$NUVB Nuvation Bio Announces Pivotal Global Phase [--] SIGMA Trial (G203) for Safusidenib in IDH1-Mutant Glioma More Info: https://pryzm.ozmosi.com/product/22745 https://pryzm.ozmosi.com/product/22745"  
[X Link](https://x.com/OzmosiHealth/status/2020860969212334197)  2026-02-09T14:02Z [----] followers, [---] engagements


"$SLDB Solid Biosciences Announces Positive Feedback from Type C Meeting with FDA for SGT-003 Gene Therapy for Duchenne Muscular Dystrophy More Info: https://pryzm.ozmosi.com/product/26382 https://pryzm.ozmosi.com/product/26382"  
[X Link](https://x.com/OzmosiHealth/status/2020860971972186152)  2026-02-09T14:02Z [----] followers, [---] engagements


"$BRCTF BLA for subcutaneous formulation of Leqembi designated for Priority Review in China More Info: https://pryzm.ozmosi.com/product/16901 https://pryzm.ozmosi.com/product/16901"  
[X Link](https://x.com/OzmosiHealth/status/2020860974593683678)  2026-02-09T14:02Z [----] followers, [---] engagements


"$COX +nan% today Nicox to Present Data from NCX [---] Phase [--] Studies at American Glaucoma Society (AGS) Annual Meeting [----] More Info: https://pryzm.ozmosi.com/product/23864 https://pryzm.ozmosi.com/product/23864"  
[X Link](https://x.com/OzmosiHealth/status/2021223333472460809)  2026-02-10T14:02Z [----] followers, [--] engagements


"$NKTR +0.63% today New REZOLVE-AD Maintenance Data in Atopic Dermatitis Demonstrate Rezpegaldesleukin Resulted in Durable and New Responses Across Key Disease Measurements with Both Monthly and Quarterly Dosing More Info: https://pryzm.ozmosi.com/product/20557 https://pryzm.ozmosi.com/product/20557"  
[X Link](https://x.com/OzmosiHealth/status/2021223336735551657)  2026-02-10T14:02Z [----] followers, [---] engagements


"$PHIO +nan% today Phio Announces Safety Monitoring Committee's (SMC) Positive Wrap-up on Lead Clinical Candidate PH-762 in Skin Cancer Trial More Info: https://pryzm.ozmosi.com/product/25034 https://pryzm.ozmosi.com/product/25034"  
[X Link](https://x.com/OzmosiHealth/status/2021223340170760460)  2026-02-10T14:02Z [----] followers, [---] engagements


"$MDCX -3.57% today Medicus Pharma Receives FDA "Study May Proceed" Clearance For Teverelix Phase 2b Study in Advanced Prostate Cancer Patients with High Cardiovascular Risk More Info: https://pryzm.ozmosi.com/product/2179 https://pryzm.ozmosi.com/product/2179"  
[X Link](https://x.com/OzmosiHealth/status/2021223342901178418)  2026-02-10T14:02Z [----] followers, [---] engagements


"$EVMN -3.04% today Evommune Announces Positive Top-line Data from Phase 2a Proof-of-Concept Trial of EVO301 in Moderate-to-Severe Atopic Dermatitis More Info: https://pryzm.ozmosi.com/product/33649 https://pryzm.ozmosi.com/product/33649"  
[X Link](https://x.com/OzmosiHealth/status/2021223345812013157)  2026-02-10T14:02Z [----] followers, [---] engagements


"$HOTH +6.76% today Hoth Therapeutics Announces Groundbreaking Positive Results: Hoth's HT-VA GDNF Surpasses Semaglutide in Weight Loss Glucose Control and Liver Health in Obesity Model More Info: https://pryzm.ozmosi.com/product/1987 https://pryzm.ozmosi.com/product/1987"  
[X Link](https://x.com/OzmosiHealth/status/2021223354599080250)  2026-02-10T14:02Z [----] followers, [---] engagements


"$ENTA +2.44% today Enanta Pharmaceuticals to Present Preclinical Data for EDP-978 its KIT Inhibitor in Development for the Treatment of Type [--] Immune Diseases at the [----] AAAAI Annual Meeting More Info: https://pryzm.ozmosi.com/product/37201 https://pryzm.ozmosi.com/product/37201"  
[X Link](https://x.com/OzmosiHealth/status/2021223358126526925)  2026-02-10T14:02Z [----] followers, [--] engagements


"$4502 +nan% today U.S. Food and Drug Administration Accepts New Drug Application and Grants Priority Review for Takeda's Oveporexton (TAK-861) as a Potential First-in-Class Therapy for Narcolepsy Type [--] More Info: https://pryzm.ozmosi.com/product/28264 https://pryzm.ozmosi.com/product/28264"  
[X Link](https://x.com/OzmosiHealth/status/2021223364074127860)  2026-02-10T14:02Z [----] followers, [---] engagements


"$MNMD up 45% today 🚀 as 20-year-old university student that made a $110 million profit with a one-month bet on Bed Bath & Beyond stock also mentions Mind Medicine Mind Medicine also with positive updates on their pipeline this summer:"  
[X Link](https://x.com/anyuser/status/1560267518337462273)  2022-08-18T14:08Z [----] followers, [--] engagements


"$OCGN Ocugen Inc. lifts clinical hold on IND for OCU200 Phase [--] Trial. More Info: $XBI $IBB $XPH $PPH https://pryzm.ozmosi.com/product/25834 https://pryzm.ozmosi.com/product/25834"  
[X Link](https://x.com/anyuser/status/1843970207108517995)  2024-10-09T11:02Z [----] followers, [---] engagements


"$VKTX Viking announced they will present P3 Type [--] DiabetesObesity results on 2025-11-08 for VK-2735 More Info: https://pryzm.ozmosi.com/product/25106 https://pryzm.ozmosi.com/product/25106"  
[X Link](https://x.com/anyuser/status/1981724735231672371)  2025-10-24T14:09Z [----] followers, [----] engagements


"$CMPX Compass Therapeutics announced they will present P1 Non-Small-Cell Lung Cancer results in 2H26 for CTX-10726 More Info: https://pryzm.ozmosi.com/product/34847 https://pryzm.ozmosi.com/product/34847"  
[X Link](https://x.com/OzmosiHealth/status/2008966912454136165)  2026-01-07T18:20Z [----] followers, [---] engagements


"$NRIX Nurix Therapeutics Outlines [----] Goals and Objectives for Advancing Bexobrutideg and Its Pipeline of Novel Degrader-Based Medicines in Cancer and Autoimmune Diseases More Info: https://pryzm.ozmosi.com/product/24726 https://pryzm.ozmosi.com/product/24726"  
[X Link](https://x.com/OzmosiHealth/status/2010714095889346959)  2026-01-12T14:02Z [----] followers, [---] engagements


"$MPLT MapLight Therapeutics announced they will present P2 Autism Spectrum Disorder results in 3Q26 for ML-004 More Info: https://pryzm.ozmosi.com/product/24000 https://pryzm.ozmosi.com/product/24000"  
[X Link](https://x.com/OzmosiHealth/status/2010812164773462339)  2026-01-12T20:32Z [----] followers, [---] engagements


"$MPLT MapLight Therapeutics announced they will present P2 Schizophrenia results in 3Q26 for ML-007 More Info: https://pryzm.ozmosi.com/product/31046 https://pryzm.ozmosi.com/product/31046"  
[X Link](https://x.com/OzmosiHealth/status/2010812167646552457)  2026-01-12T20:32Z [----] followers, [---] engagements


"$IVVD Invivyd announced they will present P3 COVID-19 results in 3Q26 for VYD-2311 More Info: https://pryzm.ozmosi.com/product/33169 https://pryzm.ozmosi.com/product/33169"  
[X Link](https://x.com/OzmosiHealth/status/2019113760083034461)  2026-02-04T18:20Z [----] followers, [---] engagements


"$ZBIO Zenas BioPharma Announces Late-Breaking Platform Presentation of Results from Phase [--] MoonStone Trial of Obexelimab in Relapsing Multiple Sclerosis at ACTRIMS Forum [----] More Info: https://pryzm.ozmosi.com/product/17691 https://pryzm.ozmosi.com/product/17691"  
[X Link](https://x.com/OzmosiHealth/status/2020860961020920178)  2026-02-09T14:02Z [----] followers, [---] engagements


"$NRSN NeuroSense Expands Global IP Protection Strategy With Granted Australian Patent Covering PrimeC Composition More Info: https://pryzm.ozmosi.com/product/28154 https://pryzm.ozmosi.com/product/28154"  
[X Link](https://x.com/OzmosiHealth/status/2020876041200525804)  2026-02-09T15:02Z [----] followers, [---] engagements


"$MSCL +nan% today Satellos Announces First Participant Dosed in Phase [--] Pediatric Study of SAT-3247 for Duchenne Muscular Dystrophy More Info: https://pryzm.ozmosi.com/product/33213 https://pryzm.ozmosi.com/product/33213"  
[X Link](https://x.com/OzmosiHealth/status/2021948094641057823)  2026-02-12T14:02Z [----] followers, [---] engagements


"$BCRX BioCryst announced they will present P2 Angioedemas Hereditary results on 2026-03-01 for Navenibart More Info: https://pryzm.ozmosi.com/product/26401 https://pryzm.ozmosi.com/product/26401"  
[X Link](https://x.com/OzmosiHealth/status/2022012869089616126)  2026-02-12T18:20Z [----] followers, [---] engagements


"$VNDA Vanda announced they will present P3 Phobia Social results in YE26 for VQW-765 More Info: https://pryzm.ozmosi.com/product/9218 https://pryzm.ozmosi.com/product/9218"  
[X Link](https://x.com/OzmosiHealth/status/2022012874672210389)  2026-02-12T18:20Z [----] followers, [---] engagements


"$Private Microbiotica presented P1 Colitis Ulcerative results on 2026-02-11 for MB-310 More Info: https://pryzm.ozmosi.com/product/26448 https://pryzm.ozmosi.com/product/26448"  
[X Link](https://x.com/OzmosiHealth/status/2022012883195113786)  2026-02-12T18:20Z [----] followers, [--] engagements


"$Private Microbiotica presented P1 Colitis Ulcerative results on 2026-02-11 for MB-310 More Info: https://pryzm.ozmosi.com/product/26448 https://pryzm.ozmosi.com/product/26448"  
[X Link](https://x.com/OzmosiHealth/status/2022012885803970653)  2026-02-12T18:20Z [----] followers, [---] engagements


"$MTVA -1.55% today MetaVia Builds Comprehensive Global Patent Protection for DA-1726 Securing Exclusive Rights to Novel Obesity and Metabolic Therapy Through [----] More Info: https://pryzm.ozmosi.com/product/31026 https://pryzm.ozmosi.com/product/31026"  
[X Link](https://x.com/OzmosiHealth/status/2022310358061621291)  2026-02-13T14:02Z [----] followers, [---] engagements


"$ALNY Alnylam announced they will present P1 Healthy Volunteers results in 2H26 for ALN-6400 More Info: https://pryzm.ozmosi.com/product/33523 https://pryzm.ozmosi.com/product/33523"  
[X Link](https://x.com/OzmosiHealth/status/2022375278836937070)  2026-02-13T18:20Z [----] followers, [--] engagements


"$ANVS Annovis Bio announced they will present P3 Alzheimer Disease results in 1H27 for Buntanetap More Info: https://pryzm.ozmosi.com/product/21508 https://pryzm.ozmosi.com/product/21508"  
[X Link](https://x.com/OzmosiHealth/status/2022375284365021451)  2026-02-13T18:20Z [----] followers, [--] engagements


"$BNTC Benitec announced they will present P1 Muscular Dystrophy Oculopharyngeal results in 3Q26 for BB-301 More Info: https://pryzm.ozmosi.com/product/27406 https://pryzm.ozmosi.com/product/27406"  
[X Link](https://x.com/OzmosiHealth/status/2022375289754615937)  2026-02-13T18:20Z [----] followers, [--] engagements


"$CRSP CRISPR Therapeutics announced they will present P1 Hypertriglyceridemia results in 2H26 for CTX-310 More Info: https://pryzm.ozmosi.com/product/26903 https://pryzm.ozmosi.com/product/26903"  
[X Link](https://x.com/OzmosiHealth/status/2022375292350988510)  2026-02-13T18:20Z [----] followers, [---] engagements


"$MRK Merck announced they will present P2 Prostate Cancer results on 2026-02-26 for Gocatamig More Info: https://pryzm.ozmosi.com/product/22936 https://pryzm.ozmosi.com/product/22936"  
[X Link](https://x.com/OzmosiHealth/status/2022375309576933858)  2026-02-13T18:20Z [----] followers, [--] engagements


"$MRK Merck announced they will present P3 Bladder Cancer results on 2026-02-26 for Enfortumab vedotin More Info: https://pryzm.ozmosi.com/product/4397 https://pryzm.ozmosi.com/product/4397"  
[X Link](https://x.com/OzmosiHealth/status/2022375315071472131)  2026-02-13T18:20Z [----] followers, [--] engagements


"$SNGX Soligenix announced they will present P3 T-Cell Lymphoma results in 2Q26 for Racepericin More Info: https://pryzm.ozmosi.com/product/18781 https://pryzm.ozmosi.com/product/18781"  
[X Link](https://x.com/OzmosiHealth/status/2022375324445753594)  2026-02-13T18:20Z [----] followers, [---] engagements


"$RARE Ultragenyx announced they will present P2 Hepatolenticular Degeneration results in YE26 for Rivunatpagene miziparvovec More Info: https://pryzm.ozmosi.com/product/25164 https://pryzm.ozmosi.com/product/25164"  
[X Link](https://x.com/OzmosiHealth/status/2022375327012618545)  2026-02-13T18:20Z [----] followers, [---] engagements


"$RARE Ultragenyx announced they will present P3 Angelman Syndrome results in 2H26 for Apazunersen More Info: https://pryzm.ozmosi.com/product/22890 https://pryzm.ozmosi.com/product/22890"  
[X Link](https://x.com/OzmosiHealth/status/2022375330133221644)  2026-02-13T18:20Z [----] followers, [---] engagements


"$UPB Upstream Bio presented P2 Asthma results on 2026-02-11 for Verekitug More Info: https://pryzm.ozmosi.com/product/26311 https://pryzm.ozmosi.com/product/26311"  
[X Link](https://x.com/OzmosiHealth/status/2022012889113276728)  2026-02-12T18:20Z [----] followers, [---] engagements


"$APRE Aprea Therapeutics announced they will present P1 Oncology Solid Tumor Unspecified results in YE26 for APR-1051 More Info: https://pryzm.ozmosi.com/product/32283 https://pryzm.ozmosi.com/product/32283"  
[X Link](https://x.com/OzmosiHealth/status/2022375287061942744)  2026-02-13T18:20Z [----] followers, [--] engagements


"$KPTI Karyopharm announced they will present P3 Endometrial Cancer results in 3Q26 for Selinexor More Info: https://pryzm.ozmosi.com/product/1982 https://pryzm.ozmosi.com/product/1982"  
[X Link](https://x.com/OzmosiHealth/status/2022375301565812963)  2026-02-13T18:20Z [----] followers, [---] engagements


"$KPTI Karyopharm announced they will present P3 Myelofibrosis results in 1Q26 for Selinexor More Info: https://pryzm.ozmosi.com/product/1982 https://pryzm.ozmosi.com/product/1982"  
[X Link](https://x.com/OzmosiHealth/status/2022375304090784148)  2026-02-13T18:20Z [----] followers, [---] engagements


"$RZLT Rezolute announced they will present P3 Hyperinsulinism results in 2H26 for Ersodetug More Info: https://pryzm.ozmosi.com/product/23871 https://pryzm.ozmosi.com/product/23871"  
[X Link](https://x.com/OzmosiHealth/status/2022375317650968865)  2026-02-13T18:20Z [----] followers, [---] engagements


"$MCRB Seres announced they will present P1 Enterocolitis results in 2Q26 for SER-155 More Info: https://pryzm.ozmosi.com/product/23510 https://pryzm.ozmosi.com/product/23510"  
[X Link](https://x.com/OzmosiHealth/status/2022375321115463721)  2026-02-13T18:20Z [----] followers, [--] engagements


"$VRTX Vertex announced they will present P2 Kidney Diseases results in 4Q26 for Inaxaplin More Info: https://pryzm.ozmosi.com/product/20855 https://pryzm.ozmosi.com/product/20855"  
[X Link](https://x.com/OzmosiHealth/status/2022375335258722549)  2026-02-13T18:20Z [----] followers, [---] engagements


"$AB AB Science receives notice of allowance for US patent covering masitinib in the treatment of metastatic castrate resistant prostate cancer More Info: https://pryzm.ozmosi.com/product/1289 https://pryzm.ozmosi.com/product/1289"  
[X Link](https://x.com/OzmosiHealth/status/2016980255882539471)  2026-01-29T21:02Z [----] followers, [---] engagements


"$GNFT GENFIT to receive US$20M milestone after Ipsen's Iqirvo exceeds the US$200M threshold in its first full year of net sales More Info: https://pryzm.ozmosi.com/product/714 https://pryzm.ozmosi.com/product/714"  
[X Link](https://x.com/OzmosiHealth/status/2022053879614234921)  2026-02-12T21:03Z [----] followers, [---] engagements


"$CRSP CRISPR Therapeutics announced they will present P1 Lupus Erythematosus SystemicMyositis results in 2H26 for Zugocaptagene Geleucel More Info: https://pryzm.ozmosi.com/product/26820 https://pryzm.ozmosi.com/product/26820"  
[X Link](https://x.com/OzmosiHealth/status/2022375295358206286)  2026-02-13T18:20Z [----] followers, [---] engagements


"$CRSP CRISPR Therapeutics announced they will present P2 Total Knee Arthroplasty results in 2H26 for SRSD-107 More Info: https://pryzm.ozmosi.com/product/31778 https://pryzm.ozmosi.com/product/31778"  
[X Link](https://x.com/OzmosiHealth/status/2022375298894098734)  2026-02-13T18:20Z [----] followers, [---] engagements


"$BBIO BridgeBio presented P3 Achondroplasia results on 2026-02-12 for Infigratinib More Info: https://pryzm.ozmosi.com/product/1090 https://pryzm.ozmosi.com/product/1090"  
[X Link](https://x.com/OzmosiHealth/status/2022375341843714345)  2026-02-13T18:20Z [----] followers, [---] engagements


"$AMLX Positive long-term results from Phase [--] HELIOS trial of AMX0035 in Wolfram syndrome announced by Amylyx Pharmaceuticals. More Info: $XBI $IBB $XPH $PPH https://pryzm.ozmosi.com/product/14195 https://pryzm.ozmosi.com/product/14195"  
[X Link](https://x.com/OzmosiHealth/status/1921891247905816948)  2025-05-12T11:32Z [----] followers, [---] engagements


"$NRSN -1.40% today as NeuroSense Receives FDA Clearance to Initiate Pivotal Phase [--] Trial for PrimeC in ALS More Info: https://pryzm.ozmosi.com/product/28154 https://pryzm.ozmosi.com/product/28154"  
[X Link](https://x.com/OzmosiHealth/status/1993064759034282166)  2025-11-24T21:10Z [----] followers, [---] engagements


"$ORIC Oric presented P1 Oncology Solid Tumor Unspecified results on 2025-12-04 for Enozertinib More Info: https://pryzm.ozmosi.com/product/25434 https://pryzm.ozmosi.com/product/25434"  
[X Link](https://x.com/OzmosiHealth/status/1997043237186363784)  2025-12-05T20:39Z [----] followers, [---] engagements


"$BRNS +7.75% today as Barinthus Bio Announces Update on Phase [--] AVALON Clinical Trial of VTP-1000 for the Treatment of Celiac Disease More Info: https://pryzm.ozmosi.com/product/27012 https://pryzm.ozmosi.com/product/27012"  
[X Link](https://x.com/OzmosiHealth/status/1998765333167931719)  2025-12-10T14:42Z [----] followers, [---] engagements


"$TNYA -2.50% today as Tenaya Therapeutics Reports Positive Interim Data from Cohort [--] of RIDGE-1 Phase 1b/2 Clinical Trial of TN-401 Gene Therapy for Adults with PKP2-associated ARVC More Info: https://pryzm.ozmosi.com/product/25601 https://pryzm.ozmosi.com/product/25601"  
[X Link](https://x.com/OzmosiHealth/status/1999238024924741642)  2025-12-11T22:01Z [----] followers, [---] engagements


"$TNYA Tenaya Therapeutics presented P1 Arrhythmogenic Right Ventricular Dysplasia results on 2025-12-11 for TN-401 More Info: https://pryzm.ozmosi.com/product/25601 https://pryzm.ozmosi.com/product/25601"  
[X Link](https://x.com/OzmosiHealth/status/1999549501082603879)  2025-12-12T18:38Z [----] followers, [---] engagements


"$HOWL Werewolf Therapeutics announced they will present P1 Oncology Solid Tumor Unspecified results in 1H26 for WTX-330 More Info: https://pryzm.ozmosi.com/product/25074 https://pryzm.ozmosi.com/product/25074"  
[X Link](https://x.com/OzmosiHealth/status/2002094807737397345)  2025-12-19T19:12Z [----] followers, [---] engagements


"$ANL +nan% today Alert Adlai Nortye Enters Exclusive License Agreement with ASK Pharm for Pan-RAS (ON) Inhibitor AN9025 in Greater China More Info: https://pryzm.ozmosi.com/product/37014 https://pryzm.ozmosi.com/product/37014"  
[X Link](https://x.com/OzmosiHealth/status/2005672917485383780)  2025-12-29T16:11Z [----] followers, [---] engagements


"$BCAB Alert BioAtla and GATC Health Announce a $40 Million Special Purpose Vehicle (SPV) Transaction to Advance Ozuriftamab Vedotin (Oz-V) into a Registrational Trial for 2L+ Oropharyngeal Squamous Cell Carcinoma (OPSCC) More Info: https://pryzm.ozmosi.com/product/20435 https://pryzm.ozmosi.com/product/20435"  
[X Link](https://x.com/OzmosiHealth/status/2006365252246507734)  2025-12-31T14:02Z [----] followers, [---] engagements


"$GANX Gain Therapeutics Highlights Biomarker Evidence Supporting Disease-Modifying Potential of GT-02287 More Info: https://pryzm.ozmosi.com/product/23956 https://pryzm.ozmosi.com/product/23956"  
[X Link](https://x.com/OzmosiHealth/status/2008539741399249307)  2026-01-06T14:02Z [----] followers, [---] engagements


"$CGTX Cognition Therapeutics Publishes Phase [--] Clinical Results Showing Zervimesine's Potential to Slow the Progression of Dementia with Lewy Bodies More Info: https://pryzm.ozmosi.com/product/17378 https://pryzm.ozmosi.com/product/17378"  
[X Link](https://x.com/OzmosiHealth/status/2008539744159101035)  2026-01-06T14:02Z [----] followers, [---] engagements


"$ZLAB Zai Lab Announces National Medical Products Administration (NMPA) Approval of AUGTYRO (repotrectinib) for Patients with NTRK-Positive Solid Tumors More Info: https://pryzm.ozmosi.com/product/16753 https://pryzm.ozmosi.com/product/16753"  
[X Link](https://x.com/OzmosiHealth/status/2008539746843455628)  2026-01-06T14:02Z [----] followers, [---] engagements


"$NBP NovaBridge Presents Positive Givastomig Dose Expansion Data from the Phase 1b Combination Study in Patients with 1L Metastatic Gastric Cancer More Info: https://pryzm.ozmosi.com/product/27189 https://pryzm.ozmosi.com/product/27189"  
[X Link](https://x.com/OzmosiHealth/status/2008539769824047426)  2026-01-06T14:02Z [----] followers, [---] engagements


"$TSHA Taysha Gene Therapies Announces Progress Across TSHA-102 Pivotal Gene Therapy Program in Rett Syndrome More Info: https://pryzm.ozmosi.com/product/26042 https://pryzm.ozmosi.com/product/26042"  
[X Link](https://x.com/OzmosiHealth/status/2008539775750599119)  2026-01-06T14:02Z [----] followers, [---] engagements


"$TIL Instil Bio's Subsidiary Discontinues Clinical Development of AXN-2510 and Terminates License and Collaboration Agreement with ImmuneOnco More Info: https://pryzm.ozmosi.com/product/24624 https://pryzm.ozmosi.com/product/24624"  
[X Link](https://x.com/OzmosiHealth/status/2008539783740747957)  2026-01-06T14:02Z [----] followers, [---] engagements


"$JAZZ Ziihera (zanidatamab-hrii) Combinations Achieve Unprecedented Results in First-Line HER2+ Locally Advanced or Metastatic GEA Including More Than Two Years Median Overall Survival Benefit More Info: https://pryzm.ozmosi.com/product/21557 https://pryzm.ozmosi.com/product/21557"  
[X Link](https://x.com/OzmosiHealth/status/2008645417630564790)  2026-01-06T21:02Z [----] followers, [---] engagements


"$NMRA Neumora announced they will present P3 Depressive Disorder Major results in 2Q26 for Navacaprant More Info: https://pryzm.ozmosi.com/product/21674 https://pryzm.ozmosi.com/product/21674"  
[X Link](https://x.com/OzmosiHealth/status/2008930706605633600)  2026-01-07T15:56Z [----] followers, [---] engagements


"$ZBIO Zenas presented P3 IgG4-related Disease results on 2026-01-05 for Obexelimab More Info: https://pryzm.ozmosi.com/product/17691 https://pryzm.ozmosi.com/product/17691"  
[X Link](https://x.com/OzmosiHealth/status/2008930714566479894)  2026-01-07T15:56Z [----] followers, [---] engagements


"$DNLI Denali Therapeutics announced they will present P1 Mucopolysaccharidosis III results on 2026-02-03 for DNL-126 More Info: https://pryzm.ozmosi.com/product/29262 https://pryzm.ozmosi.com/product/29262"  
[X Link](https://x.com/OzmosiHealth/status/2008966926358196381)  2026-01-07T18:20Z [----] followers, [---] engagements


"$TSHA Taysha Gene Therapies announced they will present P1 Rett Syndrome results in 1H26 for Lonimecgene Renparvovec More Info: https://pryzm.ozmosi.com/product/26042 https://pryzm.ozmosi.com/product/26042"  
[X Link](https://x.com/OzmosiHealth/status/2008966940274966533)  2026-01-07T18:20Z [----] followers, [---] engagements


"$ATAI ATAI Life Sciences announced they will present P2 Phobia Social results in 1Q26 for EMP-01 More Info: https://pryzm.ozmosi.com/product/26483 https://pryzm.ozmosi.com/product/26483"  
[X Link](https://x.com/OzmosiHealth/status/2009691752354197712)  2026-01-09T18:20Z [----] followers, [---] engagements


"$CLYM Climb Bio announced they will present P2 Membranous Nephropathy results in 2H26 for Budoprutug More Info: https://pryzm.ozmosi.com/product/34666 https://pryzm.ozmosi.com/product/34666"  
[X Link](https://x.com/OzmosiHealth/status/2009691765004218740)  2026-01-09T18:20Z [----] followers, [---] engagements


"$CGEM Cullinan Oncology announced they will present P1 Arthritis RheumatoidLupus Erythematosus Systemic results in 2Q26 for CLN-978 More Info: https://pryzm.ozmosi.com/product/26744 https://pryzm.ozmosi.com/product/26744"  
[X Link](https://x.com/OzmosiHealth/status/2009691767730516346)  2026-01-09T18:20Z [----] followers, [---] engagements


"$CGEM Cullinan Oncology announced they will present P1 Autoimmune Disease Unspecified results in 4Q26 for Velinotamig More Info: https://pryzm.ozmosi.com/product/25255 https://pryzm.ozmosi.com/product/25255"  
[X Link](https://x.com/OzmosiHealth/status/2009691770767192421)  2026-01-09T18:20Z [----] followers, [---] engagements


"$TRDA Entrada Therapeutics announced they will present P2 Muscular Dystrophy Duchenne results in 2Q26 for ENTR-601-44 More Info: https://pryzm.ozmosi.com/product/25129 https://pryzm.ozmosi.com/product/25129"  
[X Link](https://x.com/OzmosiHealth/status/2009691785367572966)  2026-01-09T18:20Z [----] followers, [---] engagements


"$ACTU Actuate Therapeutics Reports Positive Follow-Up Data from its Randomized Controlled Phase [--] Trial Demonstrating Extended Long-Term Overall Survival Benefit with Elraglusib Plus Chemotherapy for Metastatic Pancreatic Cancer in Oral Presentation at ASCO GI [----] More Info: https://pryzm.ozmosi.com/product/22019 https://twitter.com/i/web/status/2010714107109154859 https://pryzm.ozmosi.com/product/22019 https://twitter.com/i/web/status/2010714107109154859"  
[X Link](https://x.com/OzmosiHealth/status/2010714107109154859)  2026-01-12T14:02Z [----] followers, [---] engagements


"$HRMY Harmony Biosciences Guides to Over $1 Billion in WAKIX Revenue in 2026; Advancing Robust Late-Stage Pipeline With Potential for Long-term Value Creation More Info: https://pryzm.ozmosi.com/product/1714 https://pryzm.ozmosi.com/product/1714"  
[X Link](https://x.com/OzmosiHealth/status/2010714109667606875)  2026-01-12T14:02Z [----] followers, [---] engagements


"$CNTB Connect Biopharma Highlights New Mechanism of Action Data for Rademikibart and Outlines Priorities for [----] More Info: https://pryzm.ozmosi.com/product/19365 https://pryzm.ozmosi.com/product/19365"  
[X Link](https://x.com/OzmosiHealth/status/2010714138126029005)  2026-01-12T14:03Z [----] followers, [---] engagements


"$TNYA Tenaya Therapeutics announced they will present P1 Arrhythmogenic Right Ventricular Dysplasia results in 1H26 for TN-401 More Info: https://pryzm.ozmosi.com/product/25601 https://pryzm.ozmosi.com/product/25601"  
[X Link](https://x.com/OzmosiHealth/status/2010812175703826522)  2026-01-12T20:32Z [----] followers, [---] engagements


"$TNYA Tenaya Therapeutics announced they will present P1 Cardiomyopathy Hypertrophic results in 1H26 for TN-201 More Info: https://pryzm.ozmosi.com/product/26351 https://pryzm.ozmosi.com/product/26351"  
[X Link](https://x.com/OzmosiHealth/status/2010812178291704237)  2026-01-12T20:32Z [----] followers, [---] engagements

Limited data mode. Full metrics available with subscription: lunarcrush.com/pricing